SCHEMBL18220191

SCHEMBL18220191

COCCNS(=O)(=O)/C(C#N)=C/c1ccc(-c2ccc3cc(N4CCOCC4)ccc3c2)n1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.47
ALDH1A1 P00352 7/20 0.40
KDM4E B2RXH2 6/20 0.40
HPGD P15428 5/20 0.40
KMT2A Q03164 4/20 0.40
GAA P10253 3/20 0.40
MEN1 O00255 3/20 0.40
MAPT P10636 3/20 0.40
HTT P42858 2/20 0.40
USP2 O75604 1/20 0.40
THRB P10828 1/20 0.37
SYK P43405 4/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CASP1 P29466 2/20 0.36
NSD2 O96028 1/20 0.36
TSHR P16473 1/20 0.36
CASP7 P55210 1/20 0.36
CASP6 P55212 1/20 0.36
CA1 P00915 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25610090 0.95 APP (0.46) APPALDH1A1KDM4EHPGDKMT2A
SCHEMBL18220187 0.92 APP (0.47) APPALDH1A1KMT2AMEN1MAPT
SCHEMBL18220178 0.92 APP (0.46) APPALDH1A1KDM4EKMT2AGAA
SCHEMBL18220186 0.86 CA1 (0.37) ALDH1A1KDM4EHPGDKMT2AGAA
SCHEMBL18220192 0.86 KMT2A (0.55) APPALDH1A1KDM4EHPGDKMT2A
SCHEMBL18220221 0.85 APP (0.37) APPALDH1A1KDM4EKMT2AMEN1
SCHEMBL18221500 0.85 SYK (0.39) APPALDH1A1KDM4EKMT2AMEN1
SCHEMBL24068142 0.84 APP (0.41) APPALDH1A1KDM4EHPGDKMT2A
SCHEMBL18219867 0.84 APP (0.63) APPALDH1A1KDM4EHPGDKMT2A
SCHEMBL23134360 0.84 MAPT (0.42) APPALDH1A1KDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-20210371390-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2021-12-02 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885ALDH1A1 4151/4885KDM4E 4807/4885
US-20210371390-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885ALDH1A1 4151/4885KDM4E 4807/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885ALDH1A1 4151/4885KDM4E 4807/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885ALDH1A1 4226/4885KDM4E 4804/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885ALDH1A1 4226/4885KDM4E 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.